These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20852999)

  • 1. Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.
    Bellesso M; Costa SF; Pracchia LF; Santos Dias LC; Chamone D; Dorlhiac-Llacer PE
    Ann Hematol; 2011 Apr; 90(4):455-62. PubMed ID: 20852999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Hidalgo M; Hornedo J; Lumbreras C; Trigo JM; Colomer R; Perea S; Gómez C; Ruiz A; García-Carbonero R; Cortés-Funes H
    Cancer; 1999 Jan; 85(1):213-9. PubMed ID: 9921995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
    Girmenia C; Russo E; Carmosino I; Breccia M; Dragoni F; Latagliata R; Mecarocci S; Morano SG; Stefanizzi C; Alimena G
    Ann Hematol; 2007 Apr; 86(4):263-70. PubMed ID: 17225113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cherif H; Johansson E; Björkholm M; Kalin M
    Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G; Bamias A; Efstathiou E; Zorzou PM; Kastritis E; Kostis E; Papadimitriou C; Dimopoulos MA
    Cancer; 2005 Jun; 103(12):2629-35. PubMed ID: 15856427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR; Durand CR; Beaulac MT; Steinberg M
    Ann Pharmacother; 2011 Sep; 45(9):1094-102. PubMed ID: 21862714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
    Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
    J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
    Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
    Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
    Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
    Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
    Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
    Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
    Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.